1. Eur Respir Rev. 2017 Nov 15;26(146):170066. doi: 10.1183/16000617.0066-2017. 
Print 2017 Dec 31.

Personalised medicine for nonsmall cell lung cancer.

Mascaux C(1)(2), Tomasini P(3)(2), Greillier L(3)(2), Barlesi F(3)(2).

Author information:
(1)Aix Marseille University, Assistance Publique Hôpitaux de Marseille, 
Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France 
celine.mascaux@ap-hm.fr.
(2)Aix Marseille University, Inserm U911 CRO2, Marseille, France.
(3)Aix Marseille University, Assistance Publique Hôpitaux de Marseille, 
Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France.

Comment in
    doi: 10.1183/16000617.0088-2017.

Comment in
    doi: 10.1183/16000617.0064-2017.
    doi: 10.1183/16000617.0069-2017.

After years of standard care prescribed to cancer patients without any selection 
except the primary site and histology of the tumour, the era of precision 
medicine has revolutionised cancer care. Personalised medicine refers to the 
selection of patients for specific treatment based on the presence of specific 
biomarkers which indicate sensitivity to corresponding targeted therapies and/or 
lower toxicity risk, such that patients will have the greatest chance of 
deriving benefit from the treatments. Here, we review personalised medicine for 
nonsmall cell lung cancer.

Copyright ©ERS 2017.

DOI: 10.1183/16000617.0066-2017
PMCID: PMC9489039
PMID: 29141962 [Indexed for MEDLINE]

Conflict of interest statement: Conflict of interest: Disclosures can be found 
alongside this article at err.ersjournals.com